Photosensitisers for the photodynamic therapy of cancer and other diseases

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 12, 2001, Pages 1849-1860

  Detty, M R ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Age related macular degeneration; Cancer; Photochemotherapy; Photodynamic therapy; Phototherapy; Psoriasis

Indexed keywords

AMINOLEVULINIC ACID; ANTIBIOTIC AGENT; BACTERIOCHLORIN; BENZOPORPHYRIN DERIVATIVE; BUTHIONINE SULFOXIMINE; CATION; CHALCOGENOPYRYLIUM; CHLORINE DERIVATIVE; DYE; ETHER DERIVATIVE; GADOLINIUM TEXAPHYRIN; LUTETIUM TEXAPHYRIN; METHYLENE BLUE; NILE BLUE SULFATE; NUCLEOTIDE; PACLITAXEL; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; PHTHALOCYANINE DERIVATIVE; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PORPHYRIN DERIVATIVE; PURPURIN DERIVATIVE; RETINOIC ACID; RHODAMINE 123; TETRABROMORHODAMINE; TETRAKIS(M HYDROXYPHENYL)CHLORIN; TIN ETIOPURPURIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CANCER CENTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG TARGETING; DRUG UTILIZATION; HUMAN; HUMAN TISSUE; LIGHT; MOUSE; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PSORIASIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TREATMENT OUTCOME;

EID: 0035210777     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.12.1849     Document Type: Review

References (84)

1. Photodynamic therapy
2. How does photodynamic therapy work?
3. Photodynamic therapy for lung cancer - A review of 19 years' experience
4. Photodynamic therapy of bronchial cancers
5. Photodynamic therapy of gastrointestinal tumors: A review
6. Photodynamic therapy of malignant glioma. A review of literature
7. Evaluating the role of photodynamic therapy in the management of pancreatic cancer
8. Photodynamic therapeutics: Basic principles and clinical applications
9. A preliminary pharmacokinetic study of intravenous photofrin in patients
10. Photodynamic therapy
11. Porphyrin-based photosensitizers for use in photodynamic therapy
12. Photodynamic therapy in oncology: Mechanisms and clinical use
13. Clinical applications of photodynamic therapy
14. Fundamentals of photodynamic therapy: Cellular and biochemical aspects
15. Transmittance of nonionizing radiation in human tissue
16. Optical dosimetry for direct and interstitial photodynamic therapy of malignant tumors
17. Modeling optical and thermal distribution in tissue during laser irradiation
18. Photodynamic therapy
19. Photodynamic therapy with m-tetrahydroxyphenyl chlorin in vivo: Optimization of the therapeutic index
20. Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumor photosensitizers
21. New photosensitizers for photodynamic therapy: Combined effect of metallopurpurin derivatives and light on transplantable bladder tumors
22. Porphyrin-based photosensitizers for use in photodynamic therapy
23. Parabolic quantitative structure-activity relationships and photodynamic therapy: Application of a three-component model with clearance to the in vivo quantitative structure-activity relationships of a congeneric series pyropheophorbide derivatives used as photosensitizers for photodynamic therapy
24. Biodistribution and bioactivity of tetrapegylated meta-tetra(hydroxyphenyl)chlorin compared to native metatetra(hydroxyphenyl)chlorin in a rat liver tumor model
25. Highly selective targeting of ovarian cancer with the photosensitizer PEG-m-THPC in a rat model
26. Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated-photosensitizer PEG-m-THPC
27. Texaphyrins: Synthesis and applications
28. Texaphyrins - New drugs with diverse clinical applications in radiation and photodynamic therapy
29. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent
30. Low-dose photofrin-induced PDT offers excellent clinical response with minimal morbidity in chest wall recurrence of breast cancer
31. Photodynamic therapy in breast cancer patients: Application of SnET2 for skin metastases
32. Phthalocyanine 4(Pc4) photodynamic therapy of human OVCAR-3 tumor xenografts
33. Structure-photodynamic relationships of a series of 4-substituted zinc phthalocyanines
34. Phthalocyanine-induced photohemolysis: Structure-activity relationship and the effect of fluoride
35. Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma
36. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy
37. Relationship of mitochondrial function and cellular adenosine triphosphate levels to hematoporphyrin derivative-induced photosensitization in R3230AC mammary tumors
38. In vitro photosensitization of tumor cell enzymes by Photofrin II administered in vivo
39. Mitochondrial alterations in photodynamic therapy-resistant cells
40. Photodynamic tumor therapy: Mitochondrial benzodiazepine receptors as a therapeutic target
41. Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells
42. The role of subcellular localization in initiation of apoptosis by photodynamic therapy
43. Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy
44. Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: II. Tetraphenyl-21-selena-23-thiaporphyrin and tetraphenyl-21,23-diselenaporphyrin
45. Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: III. Tetraphenyl-21-tellura-23-thiaporphyrin: An internally-bridged porphyrin
46. Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: Part 4. Symmetrically and unsymmetrically substituted tetraphenyl-21,23-dithiaporphyrins
47. Five-coordinate complexes of 21-thiaporphyrin. The preparation, spectra and structures of iron(II), nickel(II), and copper(II) complexes
48. Synthesis of 5,20-diphenyl-10,15-bis(p-tolyl)-21-selenaporphyrin (SeDPDTPH)
49. 5,20-Bis(4-sulphophenyl)-10,15-bis(2-methoxy-4-sulfophenyl) -21-thiaporphyrin as a new potent sensitizer in photodynamic therapy
50. The new sensitizing agents for photodynamic therapy: 21-selenaporphyrin and 21-thiaporphyrin
51. Dendrimers: From design to application - A progress report
52. Photodynamic virus inactivation of blood components
53. Photo-inactivation of viruses in therapeutical plasma
54. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization
55. Non porphyrin photosensitizers in biomedicine
56. Phototoxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells
57. Photodynamic destruction of lysosomes mediated by nile blue photosensitizers
58. Lysosomal localization and mechanism of uptake of nile blue photosensitizers in tumor cells
59. Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas
60. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy
61. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation
62. Unusual retention of rhodamine 123 by mitochondria in smooth muscle and carcinoma cells
63. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by breast adenocarcinoma-derived MCF-7 cells
64. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye
65. Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitizing agent
66. 99mTc]hexakis(2-methoxyisobutylisonitrile)
67. Chalcogenapyrylium dyes as photochemotherapeutic agents. 2. Tumor uptake, mitochondrial targeting, and singlet-oxygen-induced inhibition of cytochrome c oxidase
68. Chalcogenapyrylium dyes as potential photochemotherapeutic agents. Solution studies of heavy atom effects on triplet yields, quantum efficiencies of singlet oxygen generation, rates of reaction with singlet quantum yields
69. Chalcogenapyrylium dyes as sensitizers for photodynamic therapy
70. PH-dependent chalcogenopyrylium dyes as potential sensitizers for PDT. Selective retention in tumor by exploiting pH differences between tumor and normal tissue
71. 2,4,6-Triarylchalcogenopyrylium dyes related in structure to the antitumor agent AA-1 as in vitro sensitizers for the photodynamic therapy of cancer
72. Synthesis and evaluation of chalcogenopyrylium dyes as potential sensitizers for the photodynamic therapy of cancer
73. Strategies for selective cancer photochemotherapy: Antibody-targeted and selective carcinoma cell photolysis
74. Intramitochondrial ayes allow selective in vitro photolysis of carcinoma
75. Mechanisms of mitochondrial photosensitization by the cationic dye, N,N′-bis(2-ethyl-1,3-dioxylene)-kryptocyanine (EDKC): Preferential inactivation of complex I in the electron transport chain
76. Photosensitization by 3,3′-dicyclohexyl-oxacarbocyanine iodide: Specific disruption of microtubules and inactivation of organelle motility
77. Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077
78. Mitochondrial toxicity of cationic photosensitizers for photochemotherapy
79. GRP78 induction by calcium ionophore potentiates photodynamic therapy using the mitochondrial targeting dye victoria blue BO
80. Synthesis and evaluation of novel rhodacyanine dyes that exhibit antitumor activity
81. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity
82. A selenopyrylium photosensitizer for photodynamic therapy related in structure to the antitumor agent AA1 with potent in vivo activity and no long-term skin photosensitization